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Interferon-? (IFN-y) is known to be an antiprolifer- 
ative, differentiating agent in many cell types, includ- 
ing neuroblastoma. In this study, we determined the 
effects of IFN-y on cellular growth and expression of 
insulin-like growth factor I1 (IGF-11) and IGF recep- 
tors in the human neuroblastoma cell line SH-SY5Y. 
Incubation of SH-SY5Y cells in IFN-y (20-100 U/ml) 
induced the formation of long neuritic processes. 
IFN-y treatment also induced decreases in [3H]TdR 
incorporation, as well as serum-dependent changes in 
cell number. Treatment with IFN-y reduced cell 
number 33% in the presence of serum but had no 
effect on cell number in the absence of serum. IGF-I1 
mRNA content was 60% inhibited by IFN-y, and was 
not serum dependent. The concentration of immuno- 
reactive IGF-I1 in SH-SYSY conditioned medium was 
also reduced in the presence of IFN-y, to less than 
half of control levels. In contrast, type I IGF receptor 
mRNA content was increased more than three-fold 
after treatment with IFN-y and serum. Co-incuba- 
tion in IFN-y (20-100 U/ml) and IGF-I1 (3-10 nM) 
prevented the inhibitory effects of IFN-y on [3H]TdR 
incorporation in serum-free media. Our results sug- 
gest that IFN-y may inhibit DNA synthesis and cell 
growth by interfering with an IGF-II/type I IGF re- 
ceptor autocrine growth or survival mechanism. 
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INTRODUCTION 
Gene expression is known to be influenced by the 
presence of extracellular factors which inhibit or stimu- 
stimulation of T lymphocytes and interacts with specific 
receptors which have been shown to be present on most 
mammalian cell types (Borden, 1992). The mechanism 
of growth inhibition by interferons is thought to include 
regulation of expression of cell surface antigens, intra- 
cellular enzymes, and oncogenes (Borden, 1992). Inter- 
ferons can also prolong all phases of the cell cycle and 
antagonize the mitogenic effects of platelet-derived 
growth factor (PDGF), fibroblast growth factor (FGF), 
epidermal growth factor (EGF), and insulin (Creasey et 
al., 1980; Balkwill and Taylor-Papadimitriou, 1978; Lin 
et al., 1986; Heyns et al., 1985; Shearer and Taylor- 
Papadimitriou, 1987). Collectively, these observations 
implicate IFN-7 as a general antiproliferative agent 
which can interact with and potentially regulate other 
growth factors. 
IGF-I1 is a member of the insulin family of mito- 
genic peptides which also includes insulin, IGF-I, and 
relaxin (Blundell and Humbel, 1980; DiCicco-Bloom 
and Black, 1988). Many fetal cell types and neuroblas- 
toma tissues synthesiz, and secrete IGF-I1 and divide in 
response to it, suggesting IGF-I1 can act as an autocrine 
mitogen during development and tumorigenesis (Lee et 
a]., 1990; Drago et al., 1991; Rappolee et al., 1992; 
El-Badry et al., 1989). The human neuroblastoma cell 
line, SH-SYSY (Biedler et al., 1978), expresses high 
levels of mRNA for IGF-I1 and IGF receptors (Martin et 
al., 1992), and also exhibits functional IGF-I1 binding 
sites (Mattsson et al., 1990; Recio-Pinto and Ishii, 
1988). SH-SYSY cells respond to IGF-I1 with increased 
DNA synthesis and neuritic outgrowth (Recio-Pinto et 
al., 1986; Feldman and Randolph, 1991; Recio-Pinto 
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and Ishii, 1988), and can survive in serum-free media 
(Sonnenfeld and Ishii, 1982). These observations are 
consistent with an IGF-11-mediated autocrine growth or 
survival mechanism in SH-SY5Y cells. 
IGF-I1 exerts most of its effects on cell growth via 
interaction with the type I and type I1 IGF receptors 
(Roth, 1988). The type I IGF receptor is an a-P-P-a 
tetramer, structurally similar to the insulin receptor, 
which also has an intracellular tyrosine kinase domain 
(Morgan et al., 1986). The type I IGF receptor binds 
IGF-I with the highest affinity, but also binds IGF-I1 and 
insulin with lower affinity (Steele-Perkins et al., 1988). 
The type I1 IGF receptor is comprised of a single trans- 
membrane spanning protein, identical to the cation-inde- 
pendent mannose-6 phosphate (Man-6 P) receptor 
(Morgan et al., 1987) which targets intracellular hydro- 
lytic enzymes from the Golgi apparatus to lysosomes 
(Nielsen et al., 1991). The type I1 IGF receptor binds 
IGF-I1 with the highest affinity, binds IGF-I with lower 
affinity and does not bind insulin (Roth, 1988). 
In the current study, we tested the effects of IFN-y 
on cellular growth and expression of IGF-I1 and IGF 
receptors in SH-SY5Y cells. We found that IFN-y in- 
duced the formation of long neuritic processes, inhibited 
DNA synthesis, and, in the presence of serum, decreased 
cellular proliferation. IFN-y also inhibited IGF-I1 mRNA 
and immunoreactive IGF-11, but increased type I IGF 
receptor mRNA. Exogenous addition of IGF-I1 pre- 
vented the IFN-y induced inhibition of DNA synthesis, 
in the absence of serum. Taken together, these results 
indicate that factors in serum, including IGF-11, can 
modulate the effects of IFN-y on cellular growth and that 
IFN-y may inhibit cellular growth by disrupting an IGF- 
IUtype I IGF receptor-mediated autocrine growth or sur- 
vival mechanism. 
MATERIALS AND METHODS 
Materials 
Tissue culture flasks were purchased from Corning 
Glass Works (Corning, NY) and Costar (Cambridge, 
MA). Human recombinant IFN-y was purchased from 
Boehringer Mannheim Biochemicals, Indianapolis, IN 
(Cat. no. 1050-494, 99% pure, as determined by HPLC, 
with endotoxin (LAL) < 10 EU/mg). The IFN-y was 
diluted in sterile Dulbecco’s modified Eagle’s medium 
(DME) and stored at -20°C. Restriction enzymes were 
obtained from Boehringer Mannheim and Gibco BRL 
(Gaithersburg, MD). [32P]dCTP was purchased from 
NEN Dupont (Boston, MA). Recombinant human IGF-I1 
from Bachem (Torrance, CA) or Biosource International 
(Westlake Village, CA) was stored at -70°C in 0.01 M 
acetic acid. Unless indicated, all other chemicals were 
from Sigma Chemical Company (St. Louis, MO). 
Cell Culture 
SH-SY5Y human neuroblastoma cells (Biedler et 
al., 1978) were kindly provided by Dr. Stephen Fisher, 
University of Michigan Medical Center. SH-SY5Y cells 
were cultured in DME and 10% calf serum (CS) at 37°C 
in a humidified atmosphere containing 10% CO,. 
Analysis of Cell Morphology 
To study SH-SY5Y morphology, cells were plated 
(2 x lo4 cells per T25 flask) in DME + 10% CS. After 
2 days, cells were washed twice with DME and fresh 
DME k 10% CS with 0 ,20 ,50 ,  or 100 U/ml IFN-y was 
added. Phase-contrast photomicrographs were taken on a 
Leitz Fluovert microscope (Wetzlar, Germany). After 
printing, the final magnifications were 120 X and 240 X . 
DNA Synthesis and Cell Proliferation Assays 
To determine the level of DNA synthesis, SH- 
SY5Y cells were plated in 6-wells (2.3 X lo5 cells per 
3.5-cm-diameter well) in DME + 10% CS and allowed 
to grow for 3 days. Medium was then removed, cells 
were rinsed twice with DME, and DME 2 10% CS and 
2 IFN-y (0,20,50, or 100 U/ml) and k IGF-II(l0 nM) 
was added. For measurement of DNA synthesis, 
[3H]TdR ([rnetl~yf-~HIthymidine, 6pCi, 6,700 Ci/mol, 
NEN DuPont, Boston, MA) was pipetted into each well 
and cells were incubated for 2 hr at 37°C. Cells were 
washed twice with ice-cold PBS and four times with 
ice-cold 5% trichloroacetic acid (TCA). One milliliter of 
0.1% SDS/O. 1 N NaOH was added for a 1-hr incubation 
at 37°C. A 0.5-ml aliquot of the TCA-insoluble radioac- 
tivity was measured by liquid scintillation counting on a 
2,000CA scintillation counter (Packard, Downers 
Grove, IL). The number of viable cells was determined 
from parallel wells of SH-SY5Y cells by trypan blue dye 
exclusion, as previously described (Feldman and Ran- 
dolph, 1991). 
Northern Analysis and cDNA Probes 
For Northern analysis, SH-SYSY cells were plated 
(1.8 X lo6 cells per T75 flask) in DME + 10% CS and 
maintained in culture for 7-8 days. The medium was then 
removed, cells were rinsed twice in DME, and DME 2 
10% CS and IFN-y (0, 20, 50, or 100 U/ml) was added. 
RNA was extracted 3 days after addition of IFN-y by the 
method of Chomczynski and Sacchi (1987). Northern 
analysis was performed essentially as previously de- 
scribed (Martin et al., 1991), using [3’P]dCTP-labeled 
cDNA probes (0.1-10 x lo8 cpm/pg) for IGF-I1 (bases 
1-854 of a cDNA encoding exons 7 , 8 ,  and part of 9 was 
excised with PstI) (Bell et al., 1984), type I IGF receptor 
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SH-SYSY cells cultured in serum appeared larger and 
more clustered relative to cells grown in serum-free me- 
dia, which appeared flatter and more spread out (com- 
pare Figs. 1A and B to Figs. 1E and F). In the presence 
of serum, low doses of IFN-y (20-100 U/ml) induced 
the formation of long varicose neuritic processes (Fig 1C 
and D). In serum-free media, cells exhibited short neu- 
ritic processes which were elaborated by IFN-y (20-100 
U/ml) (Figs. 1G and H). 
IFN-y also exhibited inhibitory effects on DNA 
synthesis in SH-SY5Y cells, both in the presence and 
absence of serum. In the presence of serum, a 3-day 
exposure to IFN-y (20-100 U/ml) inhibited [3H]TdR in- 
corporation per cell by 30-33% (Fig. 2A). In serum-free 
media, [3H]TdR incorporation per cell was significantly 
decreased by 63% after 3 days in 100 U/ml of IFN-y 
(Fig. 2A). Cell number data from the experiment shown 
in Figure 2A are presented in Figure 2B. In the presence 
of serum, IFN-y (20-100 U/ml) reduced cell number 13- 
39% relative to the CS control (Fig. 2B). The inhibitory 
effects of IFN-y on cell number were not associated with 
a reduction in cell viability. In serum-free media, IFN-y 
(20-100 U/ml) had no significant effect on cell number 
(Fig. 2B). Thus, a 3-day incubation in IFN-y inhibited 
DNA synthesis in the presence or absence of serum, but 
reduced cell number only when serum was present. 
A time course analysis of the effects of IFN-y (100 
U/ml) on SH-SY5Y DNA synthesis and cell number is 
presented in Figure 3. In the presence of serum, [3H]TdR 
incorporation per cell was reduced 41% relative to the 
CS control after a 1-day treatment with IFN-y, and re- 
mained lower than control levels at each subsequent time 
point throughout the 4-day incubation period (Fig. 3A). 
In serum-free media, [3H]TdR incorporation per cell was 
reduced 28% relative to the serum-free media control 
after one day in IFN-y, and remained lower thereafter 
(Fig. 3B). The effects of serum and JFN-y on cell num- 
ber followed the time course shown in Figure 3C. In 
serum alone, cell number steadily rose and, by 4 days, 
there was a 7-fold increase in cell number above the day 
0 serum-free control value. Addition of IFN-y to serum 
containing media significantly reduced cell number rel- 
ative to the serum controls at each time point. In contrast 
to the inhibitory effects of IFN-y on cell number in the 
presence of serum, IFN-y had no significant effect on 
cell number in serum-free media over the entire 4-day 
incubation period. 
Effects of IFN-y on IGF-I1 Expression 
To determine whether IFN-y altered IGF-I1 produc- 
tion in SH-SY 5Y cells, we assayed IGF-I1 protein levels 
by RIA in serum-free conditioned media only, and not in 
serum-supplemented media, which contains IGF-I1 (En- 
berg and Hall, 1984). We detected immunoreactive IGF- 
(bases 1490-2737 encoding the (Y and chains was ex- 
cised with Eco RI and HindIII) (Ullrich et al., 1986), and 
type I1 IGF receptor (the complete 9.1 kb cDNA was 
excised with SalI) (Oshima et al., 1988). A 1.8-kb PstI- 
PstI fragment of a chicken p-actin cDNA was also used 
for hybridization analysis (Cleveland et al., 1980). Indi- 
vidual Nytran membranes containing total cellular RNA 
were hybridized successively by stripping and reprobing 
as described in the manufacturer’s instructions (Schle- 
icher and Schuell, Keene, NH). Autoradiographs from 
Northern analysis were scanned by densitometry , and 
relative OD were obtained by analyzing several expo- 
sures from each experiment and averaging values in the 
linear range of the film. These values were expressed as 
a percentage of the control lane and were then divided by 
the percentage of control values obtained similarly from 
p-actin hybridizations. We found that IFN-y did not sig- 
nificantly change steady-state mRNA levels for f3-actin, 
and therefore used (3-actin mRNA content as a control 
for the amount of RNA loaded onto the gel. 
IGF-I1 Protein Secretion Assay 
RIA was performed essentially as discussed by 
Cullen and colleagues (Cullen et al., 1991). Cells were 
plated (1.8 X lo6 cells per T75 flask) and maintained in 
culture for 7-8 days. Cells were washed twice with 
DME, then 10 ml fresh DME and 0,20,50, or 100 U/ml 
IFN-y was added. After 3 days, media were collected 
and centrifuged to remove any cellular debris. PMSF 
(0.1 pg/ml) and aprotinin (2pg/ml) were added to inhibit 
protease activity. The media sample was then concen- 
trated using Centriprep-3 concentrators (MW cut-off = 
3,000 Da, Amicon, Beverly, MA), and acetic acid was 
added to a final concentration of 0.1 M before storage at 
-70°C. As previously described, binding proteins were 
separated from the IGF by double extraction with Sep- 
pak CI8  columns (Millipore, Bedford, MA) and assayed 
before and after column separation using an activated 
charcoal binding protein assay. Samples or IGF-I1 stan- 
dards, 20,000-30,000 cpm 12’I-labeled IGF-I1 (Amer- 
sham, Arlington Heights, IL), and 0.6 ng of a rat mono- 
clonal antibody against IGF-I1 (Upstate Biotechnologies, 
Inc., Lake Placid, NY) were incubated in 400 pl RIA 
buffer (1% BSA, 0.1 M NaH2P0,, pH 7.4, 0.02% so- 
dium azide) overnight. Bound IGF-I1 antibody complex 
was precipitated with 100 ~1 5% human y-globulin and 
500 pl 25% polyethylene glyco and counted in a y- 
counter. 
RESULTS 
Effects of IFN-y on Cell Morphology, DNA 
Synthesis, and Proliferation 
SH-SY5Y cell morphology was altered by serum 
and IFN-y. As early as 2 days after a media change, 
Fig. 1. Phase-contrast micrographs of SH-SY5Y cells cultured for four days in DME + 10% 
CS (a,b), DME + 10% CS + 20 U/ml IFN-y (c,d), DME (e,f), or DME + 20 U/ml IFN-y 
(g,h) taken at low (a,c,e,g) and high (b,d,f,h) magnification. Bars are 50 km. 
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Fig. 2. Dose-response of IFN-y effects on ['HH]TdR incorpo- 
ration (A) and cell number (B) in SH-SYSY cells. [3H]TdR and 
cell number from parallel wells were measured after a 3-day 
exposure to DME + 0% CS (0) or 10% CS (0) and IFN-y (0, 
20, 50, or 100 U/ml) as indicated on the x-axes. Values in (A), 
expressed as cpm per cell, are means of triplicate wells i SEM 
from the same experiment as in (B). Data in (B), expressed as 
cells X lo4, are the means k SEM of triplicate wells from a 
representative experiment performed three times. Viable cells 
in (B) were counted by trypan blue dye exclusion as reported 
(Feldman and Randolph, 1991). * P  c0.05 compared to the 0% 
CS or 10% CS control by unpaired, two-tailed t test. 
Fig. 3. Time course of IFN-y effects on ['HITdR incorpora- 
tion (A,B) and cell number (C) in SH-SYSY cells over a period 
of 4 days. f3H]TdR and cell number from parallel wells were 
measured after a 3-day exposure to DME 2 10% CS * IFN-y 
(100 U/ml), as indicated in the legends. Values in (A) and (B), 
expressed as cpm per cell, are means of triplicate wells 2 SEM 
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from a representative experiment performed four times. Data in 
(C), expressed as cells x lo', are the means t SEM of trip- 
licate wells from the same experiment as in (A) and (B). Viable 
cells in (C) were counted by trypan blue dye exclusion. *P 
<0.05 compared to the 0% CS or 10% CS controls for each 
time point by unpaired, two-tailed t test. 
494 Martin et al. 




0 20 50 100 
IFN-y (Wrnl) 
Fig. 4. RIA of IGF-I1 protein from SH-SY5Y cell conditioned 
media. Cells were incubated in DME + IFN--y (0, 20, 50, or 
100 U/ml), as indicated on x-axis, for 3 days. Media were then 
collected and concentrated, binding proteins removed, and 
IGF-I1 levels assayed. Values expressed as ng immunoreactive 
IGF-I1 per ml conditioned media are the means of two exper- 
iments t SEM. *P <0.05 compared to 0 U/ml IFN-y control 
by unpaired, two-tailed t test. 
I1 in serum-free media conditioned by SH-SY5Y cells for 
3 days at a concentration of 469 * 39.0 ng/ml (63.4 t 
5.3 nM). We observed a dose-dependent reduction in the 
amount of detectable immunoreactive IGF-I1 present af- 
ter a 3-day incubation with IFN-y in serum-free media, 
to 285 2 41.5 ng/ml (38.5 k 5.6 nM) in 50 U/ml or 217 
k 67.4 ng/ml (29.3 ? 9.1 nM) in 100 U/ml (Fig. 4). As 
described (Fig. 2B), there was no change in SH-SY5Y 
cell number with IFN-y treatment in serum-free media 
under similar plating conditions. 
IFN-y also reduced IGF-I1 expression at the mRNA 
level, We detected three major IGF-I1 mRNA transcripts 
(1.8, 4.8, 6.0 kb) by Northern analysis of total RNA 
from SH-SY5Y cells (Fig. 5), as previously reported 
(Martin et al., 1992). We detected the 6.0-kb IGF-I1 
mRNA transcript at higher levels than the 4.8- or 1.8-kb 
transcripts, and therefore measured 6.0-kb content as a 
representative value for IGF-I1 mRNA levels. In the 
presence of serum, a 3-day incubation of SH-SY5Y cells 
in 50 or 100 U/ml IFN-y induced 44% and 60% de- 
creases in 6.0-kb IGF-I1 mRNA content, respectively 
(Figs. 5 and 6). In serum-free media, 6.0-kb IGF-I1 
mRNA content was inhibited 43% and 62% by 50 and 
100 U/ml of IFN-y, respectively (Figs. 5 and 6). The 
extent to which IFN-y reduced 6.0-kb IGF-I1 mRNA 
content in serum or serum-free media was similar to the 
IFN-y induced reduction in IGF-I1 protein (compare 
Figs. 4 and 6). 
Effects of IFN-y and IGF-I1 on DNA Synthesis 
Because (1) IFN-y inhibited DNA synthesis and 
IGF-I1 expression in this study and (2) IGF-I1 had pre- 
viously been shown to stimulate DNA synthesis in SH- 
SY5Y cells (Mattsson et al., 1986). We postulated that 
IFN-y may inhibit DNA synthesis by reducing the 
amount of IGF-I1 available. We therefore tested whether 
exogenous addition of IGF-I1 could prevent IFN-y inhi- 
bition of DNA synthesis. For these experiments, cells 
were treated for 24 hr, in the presence or absence of 
serum, with IGF-I1 (3-10 nM), IFN-y (100 Ulml), or 
both. In the presence of serum, IGF-I1 had no effect on 
[3H]TdR incorporation per cell (Fig. 7A). In serum-free 
media, a 24-hr incubation in IGF-I1 increased [3H]TdR 
incorporation per cell 2.5 to 3.5-fold above the serum- 
free control (Fig. 7B). IGF-I1 also appeared to prevent 
the inhibitory effects of IFN-y on DNA synthesis, but 
only in serum-free media. In the presence of serum, ad- 
dition of IGF-I1 had no effect on IFN-y inhibition of 
DNA synthesis (Fig. 7A). In contrast, coincubation in 
IGF-I1 and IFN-y in serum-free media significantly in- 
creased [3H]TdR incorporation per cell relative to cells 
treated with IFN-y alone (Fig. 7B). 
Effects of IFN-y on IGF receptor mRNA 
By Northern analysis of total RNA, we detected an 
1 I-kb type I IGF receptor mRNA transcript in SH-SY5Y 
cells, as previously described (Fig. 8A) (Martin et al., 
1992). IFN-y regulated levels of type I IGF receptor 
mRNA, both in the presence and absence of serum. In 
the presence of serum, IFN-y induced increases in type I 
IGF receptor mRNA content, to 75% above the serum 
control in 20 U/ml and 3-fold above control in 100 U/ml 
(Fig. 8A and B). In serum-free media, IFN-y (100 U/ml) 
increased levels of type I IGF receptor mRNA by 50% 
after a 3-day incubation, whereas lower doses of IFN-y 
had no significant effect on type I IGF receptor mRNA 
content (Fig. 8B). We also detected a 9.4-kb type I1 IGF 
receptor mRNA transcript by Northern analysis of total 
RNA from SH-SY5Y cells (Martin et al., 1992). Levels 
of this transcript were unchanged by IFN-y (20- 100 
U/ml), both in the presence and absence of serum (Fig. 
9). 
DISCUSSION 
Production of IGFs and their receptors in the ner- 
vous system (Bondy et al., 1992; Baskin et al., 1988), 
coupled with IGF modulation of fetal neuronal growth 
(Svrzic and Schubert, 1991; DiCicco-Bloom and Black, 
1988), led us to speculate that expression of IGFs and 
IGF receptors may be regulated by factors which control 
neuronal growth. One such factor is IFN-y, an antiviral, 
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Fig. 5 .  Northern analysis of IGF-I1 mRNA. Cells were incu- 
bated for three days in DME + IFN-y (0, 20, 50, or 100 Uiml) 
+ 10% CS, as indicated above the lanes, and total RNA iso- 
lated. RNA (20 pg per lane) was loaded onto agarose gels, 
electrophoresed, and transferred to nylon membranes for SUC- 
cessive hybridization with 32P-labeled cDNAs for IGF-I1 and 
p-actin, as indicated. Amount of IFN-y in U/ml is indicated 
above each lane. nlRNA transcript sizes are shown at the right 
of each autoradiogram in kb. Autoradiographs exposed 3 hr 
(IGF-II/O% CS), 24 hr (p-actin/O% CS), 1.5 hr (IGF-II/lO% 
CS), and 24 hr (p-actinilO% CS). 
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Fig. 6. Densitometric analysis of IGF-I1 mRNA. Autoradio- 
graphs from multiple exposures of the experiment shown in 
Figure 5 and an additional experiment were quantitated using 
relative OD as described in Materials and Methods. Values are 
means ? SEM expressed as a percentage of control relative 
OD of the 6.0-kb IGF-11 mRNA transcript divided by relative 
OD of p-actin. *P <0.05 compared to 0% CS (0) or 10% CS 
(0)  control by unpaired, two-tailed t test. 
antiproliferative agent produced by mitogenic stimula- 
tion of T lymphocytes (Borden, 1992). IFN-y inhibits 
DNA synthesis and promotes differentiation of many cell 
types, including neuroblastoma cells (Borden, 1992; Wa- 
tanabe et al., 1989; Parodi et al., 1989; Ponzoni et al., 
1992). The mitogenic activity of PDGF, EGF, or basic 
FGF on human fibroblasts (Howang, 1988; Oleszak, 
1988) and vascular smooth muscle cells (Warner et al., 
1989) is blocked by IFN-y. Similarly, in human colon 
cancer cells, interferons block insulin-stimulated growth 
(Hamburger et al., 1988). We hypothesized that IFN-y 
would arrest neuronal growth by disrupting expression of 
the endogenously produced mitogenic growth factor 
IGF-11, or its receptors. 
We tested this hypothesis using the SH-SYSY hu- 
man neuroblastoma cell line (Biedler et al., 1978), which 
expresses IGF-I1 mRNA and IGF receptors (Martin et 
al., 1992). The utility of SH-SYSY cells for studying 
neuronal development and differentiation is well docu- 
mented (for review, see PBhlman et al, 1990). The SH- 
SYSY cell line synthesizes a number of neuron-specific 
proteins, including neurofilaments, noradrenergic , and 
catecholaminergic neurotransmitters, cholinergic recep- 
tors, the growth cone associated protein GAP-43, and 
neuron-specific enolase (Pihlman et a]., 1990). Morpho- 
logical and biochemical differentiation of SH-SYSY 
cells, characterized in part by increased neurite forma- 
tion and elevated levels of noradrenalin and neuron-spe- 
cific enolase, can be induced by retinoic acid and the 
phorbol ester 12-0-tetradecanoyl-phorbol- 1 3-acetate 
(Pihlman et al., 1984). 
We report that low doses of TFN-y (20-100 U/ml) 
significantly inhibited DNA synthesis as measured by 
[3H]TdR incorporation in SH-SYSY neuroblastoma 
cells, both in the presence and absence of serum. Our 
observation that a 1-day exposure to IFN-y inhibited 
DNA synthesis is consistent with an earlier finding in 
fibroblasts that brief (18 hr) incubations in low doses (10 
U/ml) of IFN-y significantly reduce DNA synthesis (Ru- 
bin and Gupta, 1980). Moreover, our resuIts demonstrate 
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Fig. 7. Effects of IGF-II and IFN-y on [3H]TdR incorporation 
in SH-SY5Y cells in media supplemented with serum (A) or 
serum-free media (B). [3H]TdR incorporation and cell number 
were measured in parallel wells after a 24-hr exposure to DME 
(B) + 10% CS (A) -C IFN-y (100 U/ml) L IGF-I1 (3-10 nM), 
as indicated on the x-axis. Values expressed as cpm per cell are 
means of duplicate wells * SEM from a representative exper- 
iment performed twice. *P <0.05 compared to 0% CS or 10% 
CS control, ** P <0.05 compared to IFN-y alone by unpaired, 
two-tailed t test. 
p-actin -2.1 
0 20 50 100 
IFN-y (U/ml) 
Fig. 8. Northern analysis of type I IGF receptor mRNA. SH- 
SY5Y cells were incubated for three days in DME + 10% CS 
+ IFN-y (0, 20, 50, or 100 U/ml) and total RNA isolated. 
RNA (20 pg per lane) was loaded onto agarose gels as de- 
scribed in Figure 5, and successively hybridized with 32P-la- 
beled cDNA probes for type I IGF receptor and p-actin, as 
indicated in (A). Amount of IFN-y in U/ml is indicated above 
each lane. mRNA transcript sizes are shown at the right of each 
autoradiogram in kb. Autoradiographs exposed 4 days (type I 
receptor) and 24 hr (p-actin). Densitometric analysis in (B) 
shows type I IGF receptor mRNA after IF"-y with (0)  and 
without (0) 10% CS. Autoradiographs from multiple exposures 
of the experiment from (A) and an additional experiment were 
quantitated as described in Figure 6. Values are means -C SEM 
relative OD expressed as a percentage of the control (0 U/ml) 
1 I-kb type I IGF receptor mRNA transcript divided by p-actin. 
*P c0.05 compared to the (0 U/ml) control by unpaired, two- 
tailed t test. 
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effects on cultured cells (Tyring et al., 1982; Balkwill 
and Bokhon'ko, 1984). We previously reported that SH- 
SYSY cells synthesize DNA but do not proliferate under 
serum free conditions (Martin and Feldman, 1992). In 
the current study, IFN-y treatment of serum-deprived 
cells inhibited DNA synthesis, again implying a block at 
G,G,. The lack of IFN-y effects on SH-SYSY cell num- 
ber was expected (given these cells do not divide in 
serum-free media), supporting a cytostatic, not cyto- 
toxic, mechanism of IFN-y action (Shearer and Taylor- 
Papadimitriou, 1987). 
The inhibitory effects of IFN-y on DNA synthesis 
and cell number imply disruption of the SH-SYSY cell 
cycle. Indeed, interferons have been shown to alter the 
effects of peptides which control progression through 
G,G, and S.  For example, interferon treatment blocks 
the ability of PDGF, EGF, or FGF to stimulate passage 
of quiescent fibroblasts through GoG, + S (Howang, 
1988; Heyns et al., 1985; Oleszak, 1988). The extent to 
which interferon inhibits mitogenic activity decreases in 
the presence of increasing numbers of mitogenic growth 
factors (Taylor-Papadimitriou, 1983). Since the insulin 
family of mitogenic growth factors specifically stimu- 
lates entry of neuroblasts into S phase (DiCicco-Bloom 
and Black, 1988), we speculated that IFN-y could reduce 
neuroblastoma growth by interfering with the autocrine 
actions of IGF-11. Previous studies have shown that SH- 
SYSY cells express mRNA for IGF-I1 and IGF receptors 
(Martin et al., 1992) as well as functional IGF-I1 binding 
sites (Mattsson et al., 1990; Recio-Pinto and Ishii, 
1988), leading to the proposed autocrine role for IGF-I1 
in mediating SH-SYSY cellular growth or survival. Our 
finding that SH-SYSY cells also synthesize and secrete 
immunoreactive IGF-I1 further supports this hypothesis. 
DNA synthesis in serum-deprived SH-SYSY cells could 
result from stimulation by endogenously produced and 
secreted IGF-11. In this way, SH-SYSY neuroblastoma 
cells may use IGF-I1 as an autocrine mitogenic growth or 
survival factor similar to its role in other neuroblastoma 
cells (El-Badry et al., 1989). We speculated that IFN-y 
effects on cell growth are mediated by changes in IGF-I1 
production. By RIA of SH-SYSY conditioned media, we 
observed a decrease in immunoreactive IGF-I1 protein 
after IFN-y treatment, under conditions where cell num- 
ber did not change. Therefore, the decrease in immuno- 
reactive IGF-I1 observed after IFN-y treatment is not 
explained by a decrease in cell number. Decreased 
IGF-I1 protein has also been observed in the liver during 
other conditions of growth inhibition, i.e., after dexa- 
methasone treatment (Levinovitz and Norstedt, 1989) or 
fasting (Straus et al., 1991), and in muscle cells after 
differentiation by basic FGF (Rosenthal et al., 1991). 
To determine whether IFN-y inhibition of IGF-I1 
expression also occurred at the mRNA level, we per- 
1 
0 0% cs 
10% cs 
0 '  I I I I 
0 20 50 160 
IFNy (U/rnl) 
Fig. 9. Densitometric analysis of type I1 IGF receptor mRNA. 
SH-SYSY cells were treated for 3 days in DME (0) + 10% CS 
(0)  + IFN-y (0,  20, 50, or 100 Uiml) and Northern analysis 
was performed as described for Figure 8. Membranes were 
successively hybridized with 32P-labeled cDNA probes for 
type I1 IGF receptor and p-actin. Autoradiographs from mul- 
tiple exposures in two experiments were quantitated as de- 
scribed in Figure 6. Values are means i SEM expressed as a 
percentage of control relative OD of the 9.4-kb type I1 IGF 
transcript, divided by the relative OD of p-actin. 
that neuroblastoma cell DNA synthesis is sensitive to 
IFN-y sooner than the 6-day treatment shown to inhibit 
DNA synthesis in Lan-1 neuroblastoma cells (Parodi et 
al., 1989). Previous studies have demonstrated the role 
of IFN-y as a DNA synthesis blocker in a variety of other 
normal and malignant cell types, including fibroblasts 
(Balkwill and Taylor-Papadimitriou, 1978), smooth 
muscle cells (Warner et al., 1989), mesangial cells (Kak- 
izaki et al., 1991), and colon cancer cells (Hamburger et 
al., 1988). 
The mechanism of growth inhibition by IFN-y is 
thought to invclve disruption of the cell cycle (Shearer 
and Taylor-Papadimitriou, 1987). IFN-y decreases the 
transition rate of cells from G,G, into S phase and pro- 
longs the time cells remain in S (Balkwill and 
Bokhon'ko, 1984; Creasey et al., 1980). Thus, IFN-y 
inhibition of DNA synthesis in serum-stimulated SH- 
SYSY cells may be secondary to a block and/or de- 
creased transition time of the cell cycle in G,G,. Pertur- 
bation of G,G, alone, or in combination with 
lengthening of S,  would also account for the reduction in 
SH-SYSY cell number which occurred after 2 days in 
IFN-y and serum. We observed no cytotoxic effects of 
IFN-y on SH-SYSY cells at doses which inhibited cell 
growth. This compares favorably to previous work 
showing IFN-y treatment at doses as high as 700 U/ml 
and for exposure times as long as 7 days had no toxic 
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formed Northern analysis on RNA from SH-SY5Y cells 
treated with and without IFN-y. We found that IFN-y 
significantly reduces steady-state levels of the 6.0-kb 
IGF-I1 mRNA transcript, in the presence or absence of 
serum. Decreased levels of the 6.0-kb IGF-I1 mRNA 
after IFN-y treatment could reflect a decrease in the rate 
of DNA transcription into RNA or a decrease in IGF-I1 
mRNA stability. The 6.0-kb IGF-I1 mRNA transcript is 
one of six (5.3, 5.0, 6.0, 2.2, 4.8, 1.8 kb) mRNAs 
transcribed from the nine exons of the human IGF-I1 
gene (Jansen et al., 1990). The 6.0-kb IGF-I1 mRNA 
transcript is produced by activity at the P3 promoter, one 
of four (Pl-P4) active IGF-I1 gene promoters (Sussen- 
bach et al., 1991). Activity at these promoters is regu- 
lated by tissue and development-specific events, P3 be- 
ing the most active and producing the 6.0-kb transcript as 
the major human IGF-I1 mRNA (Jansen et al., 1990). 
We also detected the 4.8-kb and 1.8-kb IGF-I1 mRNA 
transcripts in SH-SY5Y cells, albeit at much lower levels 
than the 6.0-kb IGF-I1 mRNA transcript. There is some 
controversy over whether the 4.8-kb human IGF-I1 
mRNA transcript derives from promoter P4 (Jansen et 
al., 1990) or arises form cross-hybridization with rRNA 
(Irminger et al., 1987); however, this transcript is 
present in fetal tissues by Northern analysis of 
poly(A)+RNA (Sandberg et al., 1988). The 1.8-kb 
IGF-11 mRNA transcript is thought to arise from cleav- 
age of larger mRNAs, and may regulate total IGF-I1 
mRNA content (Sussenbach et al., 1991). 
Our finding that IFN-y down-regulated IGF-I1 
mRNA indicates that the mechanism of interferon 
growth inhibition may include not only interference with 
the mitogenic activity of certain growth factors (Oleszak, 
1988; Howang, 1988; Heyns et al., 1985), but also reg- 
ulation of endogenous growth factor production. IFN-y 
could interfere with positive regulators of IGF-I1 mRNA, 
including ACTH, which stimulates IGF-I1 mRNA in pri- 
mary human adrenal cells (Voutilainen and Miller, 1987) 
or growth hormone, which up-regulates IGF-I1 mRNA in 
hypophysectomized rat brain (Hynes et al., 1987). Sub- 
stances other than IFN-y which are known to inhibit 
IGF-I1 mRNA expression include basic FGF, which de- 
creases IGF-I1 mRNA during differentiation of mouse 
muscle cells (Rosenthal et al., 1991) and the androgen 
steroid dihydrotestosterone, which decreases IGF-I1 
mRNA production with growth inhibition in neonatal rat 
liver (Martinoli and Pelletier, 1991). 
IFN-y inhibited IGF-I1 expression and DNA syn- 
thesis under similar experimental conditions, suggesting 
to us there may be a causal relationship between these 
two events. We were interested, therefore, in determin- 
ing whether exogenous addition of IGF-I1 could prevent 
IFN-y inhibition of DNA synthesis. Previous experi- 
ments showed that IGF-I1 (0.4-40 nM) stimulates total 
[3H]TdR incorporation in SH-SY5Y cells by 50% after a 
24-hr incubation (Mattsson et al., 1986), similar to its 
effects in cultured fetal neuroblasts (DiCicco-Bloom and 
Black, 1988; Lenoir and Honegger, 1983). We observed 
a much greater (2- to 3-fold) increase in DNA synthesis 
after a 24-hr treatment with IGF-11, but only in serum- 
free media. Addition of IGF-I1 also prevented IFN-y 
inhibition of DNA synthesis in the absence of serum. 
However, in the presence of serum, IGF-I1 did not sig- 
nificantly alter the decrease in DNA synthesis induced by 
IFN-y. These results imply that excess addition of IGF-I1 
can overcome the cytostatic effects of IFN-y, but only in 
the absence of serum. In serum, there is a family of 
binding proteins with higher affinity for the IGFs than for 
the IGF receptors. Designated IGF-BPs, these proteins 
regulate the cellular distribution of IGFs and the binding 
of IGFs to IGF receptors (Clemmons, 1991). IGF-I1 
added to serum-deprived cells is more likely to interact 
with IGF receptors, whereas IGF-I1 added to serum stim- 
ulated cells has a higher probability of interacting with 
IGF-BPs present in serum. Thus, IGF-I1 may exhibit 
increased bioavailability for SH-SY5Y cells under con- 
ditions of serum deprivation, which would explain its 
ability to prevent IFN-y inhibition of DNA synthesis. 
Differentiation of neural crest-derived cells occurs 
at a time in development when cells cease to divide 
(Sauer, 1935). IFN-y inhibition of cell growth may 
therefore indicate a differentiation pathway in SH-SY5Y 
cells. We observed that low doses of IFN-y (20-100 
U/ml) induced the formation of long varicose neuritic 
processes in the presence of serum, and enhanced neu- 
ritic process formation in serum-free media. These re- 
sults indicate that IFN-y promotes morphological differ- 
entiation of SH-SY5Y cells, as reported in other human 
neuroblastoma cell lines (Ponzoni et al., 1992; Watanabe 
et al., 1989; Parodi et al., 1989). The exact mechanisms 
underlying these phenomena are not known. In human 
GOT0 and KP-N-RT neuroblastoma cells, IFN-y en- 
hancement of differentiation is coupled to suppression of 
the N-myc gene (Watanabe et al., 1989). suggesting an 
association between IFN-y growth arrest and loss of on- 
cogene activity. IFN-y treatment of Lan- 1 human neu- 
roblastoma cells reduces expression of neuroblastoma- 
specific cell surface antigens and increases the 
expression of Lan- 1 neuronal cytoskeletal proteins, in- 
cluding neurofilaments and microtubule associated pro- 
teins (Parodi et al., 1989). Further evidence that IFN-y 
promotes differentiation of SH-SY5Y cells is our finding 
that type I IGF receptor mRNA content is increased by 
IFN-y. Ota and colleagues have reported a correlation 
between increased type I IGF receptor mRNA and in- 
duction of differentiation by phorbol esters in SH-SYSY 
cells (Ota et al., 1989), and there is evidence that IGF-I1 
mitogenicity and binding to the type I IGF receptor are 
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Fibroblast growth factor-mediated proliferation of central ner- 
vous system precursors depends on endogenous production of 
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2203. 
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Israel MA (1989): Autonomous growth of a human neuroblas- 
toma cell line is mediated by insulin-like growth factor 11. J 
Clin Invest 84:829-839. 
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uraemia. Acta Endocrinol 107:165-170. 
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modulated during phorbol ester-induced differentiation 
(Mattsson et al., 1986; PBhlman et al., 1991). Moreover, 
we observed that incubation of SH-SYSY cells in IFN-y 
(100 U/ml) and serum for 3 days increased the secreted 
activity of tissue-type plasminogen activator (unpub- 
lished observations), an event which occurs in associa- 
tion with differentiation of neuroblastoma cells (Neuman 
et al., 1989). 
In summary, the results of experiments presented 
here demonstrate that SH-SYSY cells synthesize immu- 
noreactive IGF-I1 and other components of an IGF-II- 
mediated autocrine growth or survival mechanism. Sim- 
ilarly, other neuroblastoma cells and some fetal tissues 
have been shown to use IGF-I1 as an autocrine growth 
factor (El-Badry et al., 1989; Rappolee et al., 1992; 
Minniti et al., 1992). We demonstrated that IGF-I1 ex- 
pression is negatively regulated by IFN-y, both in the 
presence and absence of serum. Because exogenous ad- 
dition of IGF-I1 prevented the inhibitory effects of IFN-y 
on DNA synthesis in serum-free media, it is possible that 
IFN-y interferes with autocrine IGF-11-mediated cellular 
growth. Further experiments will reveal whether IFN-y 
also disrupts IGF-I1 binding to the type I or I1 IGF re- 
ceptors, as shown for the antineoplastic agent suramin 
(Minniti et al., 1992). A better understanding of the 
mechanism by which IFN-y regulates IGF-I1 expression 
may lead to improved treatment therapies for neuroblas- 
toma and early developmental disorders. 
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